Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations.

导出 LinkOut

翻译打印收藏纠错

作者： Grigorios,Tsaknakis ^[1] ; Erasmia,Boutakoglou ^[1] ; Irene,Mavroudi ^[1] ; Christos S,Mantzoros ^[2] ; Maria Veiga-da,Cunha ^[3] ; Helen A,Papadaki ^[4]

作者单位： Hemopoiesis Research Laboratory, School of Medicine, University of Crete, Department of Hematology, University Hospital of Heraklion, Heraklion, Crete, Greece. ^[1] Human Nutrition and Metabolism Laboratory, Department of Medicine, Beth Israel deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States of America. ^[2] Metabolic Research Group, de Duve Institute, UC Louvain, Brussels, Belgium. ^[3] Hemopoiesis Research Laboratory, School of Medicine, University of Crete, Department of Hematology, University Hospital of Heraklion, Heraklion, Crete, Greece. Electronic address: e.papadaki@uoc.gr. ^[4]

关键词 Empagliflozin G6PC3 SGLT-2 inhibitor Severe congenital neutropenia

DOI 10.1016/j.metabol.2024.156077

PMID 39557394

发布时间 2024-12-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Metabolism

2025年162卷

156077页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations.

Metabolism

相似文献

Metabolism

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Successful repurposing of empagliflozin to treat neutropenia in a severe congenital neutropenia patient with G6PC3 mutations.

Metabolism

相似文献

Metabolism

相关期刊

检索历史清除